Literature DB >> 24197924

Non-carcinogenic effects of inorganic arsenic.

C O Abernathy1, E V Ohanian.   

Abstract

This review will focus primarily on ohe effects of the inorganic arsenicals (arsenate and arsenite forms) that are present in drinking water. They are acutely toxic to both humans and animals, an effect that may be related to their bioavailibility. In humans, arsenicals have been reported to cause dermatitis and mucous membrane irritation upon exposure. They have also been reported to cause skin lesions and peripheral neurotoxicity in smelter workers and in patients treated with Fowler's Solution. When humans are exposed to arsenic in drinking water, effects such as hyperkeratosis, electromyographic abnormalities and vascular effects have been reported. In experimental animals, arsenic has been demonstrated to affect the liver and kidneys. In mice, arsenic has also been reported to decrease the animal's resistance to certain viral infections. The arsenite (+3) and arsenate (+5) forms have different modes of action. Arsenite binds to sulphhydryl groups and has been reported to inhibit over 100 different enzymes, while the arsenate can substitute for phosphate in various high energy intermediates, resulting in arsenolysis. In addition, when arsenate is reduced to arsenite in the body, it can also cause toxicity as that species.

Entities:  

Year:  1992        PMID: 24197924     DOI: 10.1007/BF01783626

Source DB:  PubMed          Journal:  Environ Geochem Health        ISSN: 0269-4042            Impact factor:   4.609


  44 in total

1.  Peripheral neuropathy caused by arsenical intoxication; a study of 41 cases with observations on the effects of BAL (2, 3, dimercapto-propanol).

Authors:  A HEYMAN; J B PFEIFFER; R W WILLETT; H M TAYLOR
Journal:  N Engl J Med       Date:  1956-03-01       Impact factor: 91.245

2.  BAL alleviation of arsenate-induced teratogenesis in mice.

Authors:  R D Hood; C T Pike
Journal:  Teratology       Date:  1972-10

3.  Case report: an arsenic murder.

Authors:  L R Bednarczyk; W Matusiak
Journal:  J Anal Toxicol       Date:  1982 Sep-Oct       Impact factor: 3.367

4.  Acute toxicity and skin corrosion data for some organic and inorganic compounds and aqueous solutions.

Authors:  E H Vernot; J D MacEwen; C C Haun; E R Kinkead
Journal:  Toxicol Appl Pharmacol       Date:  1977-11       Impact factor: 4.219

5.  Chronic arsenic toxicity from drinking tubewell water in rural West Bengal.

Authors:  D N Guha Mazumder; A K Chakraborty; A Ghose; J D Gupta; D P Chakraborty; S B Dey; N Chattopadhyay
Journal:  Bull World Health Organ       Date:  1988       Impact factor: 9.408

6.  Trypanothione is the primary target for arsenical drugs against African trypanosomes.

Authors:  A H Fairlamb; G B Henderson; A Cerami
Journal:  Proc Natl Acad Sci U S A       Date:  1989-04       Impact factor: 11.205

Review 7.  Clinical and environmental aspects of arsenic toxicity.

Authors:  J T Hindmarsh; R F McCurdy
Journal:  Crit Rev Clin Lab Sci       Date:  1986       Impact factor: 6.250

8.  Death by arsenic: a comparative evaluation of exhumed body tissues in the presence of external contamination.

Authors:  J N Pirl; G F Townsend; A K Valaitis; D Grohlich; J J Spikes
Journal:  J Anal Toxicol       Date:  1983 Sep-Oct       Impact factor: 3.367

9.  Arsenic poisoning from anti-asthmatic herbal preparations.

Authors:  C H Tay; C S Seah
Journal:  Med J Aust       Date:  1975-09-13       Impact factor: 7.738

10.  Effects and dose--response relationships of skin cancer and blackfoot disease with arsenic.

Authors:  W P Tseng
Journal:  Environ Health Perspect       Date:  1977-08       Impact factor: 9.031

View more
  1 in total

1.  Circulating Arsenic is Associated with Long-Term Risk of Graft Failure in Kidney Transplant Recipients: A Prospective Cohort Study.

Authors:  Camilo G Sotomayor; Dion Groothof; Joppe J Vodegel; Tomás A Gacitúa; António W Gomes-Neto; Maryse C J Osté; Robert A Pol; Catterina Ferreccio; Stefan P Berger; Guillermo Chong; Riemer H J A Slart; Ramón Rodrigo; Gerjan J Navis; Daan J Touw; Stephan J L Bakker
Journal:  J Clin Med       Date:  2020-02-03       Impact factor: 4.241

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.